Business Description
Ocumension Therapeutics
ISIN : KYG674111011
Description
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 63.43 | |||||
Equity-to-Asset | 0.92 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.06 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 3.52 | |||||
Beneish M-Score | -2.45 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 101.1 | |||||
3-Year EBITDA Growth Rate | 60.6 | |||||
3-Year EPS without NRI Growth Rate | 57.3 | |||||
3-Year FCF Growth Rate | 23.5 | |||||
3-Year Book Growth Rate | -1.8 | |||||
Future 3-5Y Total Revenue Growth Rate | 88.19 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 14.25 | |||||
9-Day RSI | 23.96 | |||||
14-Day RSI | 30.96 | |||||
6-1 Month Momentum % | -23.56 | |||||
12-1 Month Momentum % | -21.72 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.35 | |||||
Quick Ratio | 5 | |||||
Cash Ratio | 4.33 | |||||
Days Inventory | 131.71 | |||||
Days Sales Outstanding | 137.43 | |||||
Days Payable | 93.22 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.4 | |||||
Shareholder Yield % | -1.48 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 58.28 | |||||
Operating Margin % | -108.97 | |||||
Net Margin % | -104.12 | |||||
FCF Margin % | -150.52 | |||||
ROE % | -11.45 | |||||
ROA % | -10.39 | |||||
ROIC % | -16.66 | |||||
ROC (Joel Greenblatt) % | -68.29 | |||||
ROCE % | -11.2 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 8.6 | |||||
PB Ratio | 1 | |||||
Price-to-Tangible-Book | 1.77 | |||||
EV-to-EBIT | -7.23 | |||||
EV-to-EBITDA | -9.04 | |||||
EV-to-Revenue | 7.46 | |||||
EV-to-FCF | -4.96 | |||||
Price-to-Net-Current-Asset-Value | 2.94 | |||||
Price-to-Net-Cash | 3.87 | |||||
Earnings Yield (Greenblatt) % | -13.83 | |||||
FCF Yield % | -14.34 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Ocumension Therapeutics Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil HK$) | 336.504 | ||
EPS (TTM) (HK$) | -0.543 | ||
Beta | 1.18 | ||
Volatility % | 46.82 | ||
14-Day RSI | 30.96 | ||
14-Day ATR (HK$) | 0.239329 | ||
20-Day SMA (HK$) | 4.9175 | ||
12-1 Month Momentum % | -21.72 | ||
52-Week Range (HK$) | 4.13 - 7.54 | ||
Shares Outstanding (Mil) | 800.9 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Ocumension Therapeutics Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Ocumension Therapeutics Stock Events
Event | Date | Price(HK$) | ||
---|---|---|---|---|
No Event Data |
Ocumension Therapeutics Frequently Asked Questions
What is Ocumension Therapeutics(HKSE:01477)'s stock price today?
When is next earnings date of Ocumension Therapeutics(HKSE:01477)?
Does Ocumension Therapeutics(HKSE:01477) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |